Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition |
On March16, 2017, Inotek Pharmaceuticals Corporation announced
its financial results for the year ended December31, 2016. A copy
of the press release is being furnished as Exhibit 99.1 to this
Report on Form 8-K.
The information in this Report on Form 8-K and Exhibit 99.1
attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or
the Exchange Act, except as expressly set forth by specific
reference in such filing.
| Item9.01 | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
| 99.1 |
Press release issued by Inotek Pharmaceuticals Corporation on March16, 2017, furnished herewith. |
About Inotek Pharmaceuticals Corporation (NASDAQ:ITEK)
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases. Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) Recent Trading Information
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) closed its last trading session down -0.02 at 1.73 with 667,734 shares trading hands.